Get the Stockscreener App
5.06
8.83%
-0.49
After Hours:
5.10
0.04
+0.79%
Aardvark Therapeutics Inc stock is traded at $5.06, with a volume of 71,449.
It is down -8.83% in the last 24 hours and down -30.21% over the past month.
Aardvark Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing novel, small-molecule therapeutics to activate innate homeostatic pathways for the treatment of metabolic diseases. It is focused on on developing selective compounds, targeting Bitter Taste Receptors (TAS2Rs) for hunger-associated conditions. Its product candidate, ARD-101, is an oral gut-restricted small-molecule agonist of certain TAS2Rs expressed in the gut lumen for which have initiated a Phase 3 clinical trial for hyperphagia associated with PWS.
See More
Previous Close:
$5.55
Open:
$5.57
24h Volume:
71,449
Relative Volume:
0.29
Market Cap:
$110.74M
Revenue:
-
Net Income/Loss:
$-69.87M
P/E Ratio:
-1.5769
EPS:
-3.2089
Net Cash Flow:
$-61.75M
1W Performance:
-5.95%
1M Performance:
-30.21%
6M Performance:
+42.94%
1Y Performance:
-60.06%
1-Day Range:
$5.02
$5.60
1-Week Range:
$5.02
$5.84
52-Week Range:
$3.35
$17.94
Aardvark Therapeutics Inc Stock (AARD) Company Profile
Name
Aardvark Therapeutics Inc
Sector
Industry
Phone
(858) 225-7696
Address
4370 LA JOLLA VILLAGE DRIVE, SAN DIEGO
Compare AARD vs VRTX, REGN, MRNA, ARGX, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
AARD
Aardvark Therapeutics Inc
|
5.06 | 110.74M | 0 | -69.87M | -61.75M | -3.2089 |
VRTX
Vertex Pharmaceuticals Inc
|
526.19 | 133.37B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
788.04 | 81.13B | 14.92B | 4.42B | 3.79B | 41.04 |
MRNA
Moderna Inc
|
198.88 | 79.40B | 2.23B | -3.19B | -1.60B | -8.1462 |
ARGX
Argen X Se Adr
|
959.49 | 60.03B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
204.97 | 43.93B | 742.00K | -1.37B | -1.07B | -7.0731 |
Aardvark Therapeutics Inc Stock (AARD) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-02-26 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Mar-02-26 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Mar-02-26 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Mar-02-26 | Downgrade | Stifel | Buy → Hold |
| Jan-28-26 | Initiated | B. Riley Securities | Buy |
| Dec-23-25 | Initiated | Oppenheimer | Outperform |
| Dec-12-25 | Initiated | William Blair | Outperform |
| Dec-03-25 | Initiated | Raymond James | Strong Buy |
| Nov-07-25 | Initiated | BTIG Research | Buy |
| Sep-29-25 | Initiated | Stifel | Buy |
| Jun-30-25 | Initiated | H.C. Wainwright | Buy |
| Mar-10-25 | Initiated | BofA Securities | Buy |
| Mar-10-25 | Initiated | Cantor Fitzgerald | Overweight |
| Mar-10-25 | Initiated | Morgan Stanley | Overweight |
| Mar-10-25 | Initiated | RBC Capital Mkts | Outperform |
View All
Aardvark Therapeutics Inc Stock (AARD) Latest News
Aardvark Therapeutics, Inc. (AARD) Investors with Substantial Losses Have Opportunity to Lead Aardvark Class Action Lawsuit - PR Newswire
Bronstein, Gewirtz & Grossman LLC Urges Aardvark Therapeutics, Inc. Investors to Act: Class Action Filed Alleging Investor Harm - lincolnjournal.com
October 13, 2026 Deadline: Join Class Action Lawsuit Against Aardvark Therapeutics, Inc. (AARD)Contact Levi & Korsinsky - accessnewswire.com
Investors Urged to Contact Levi & Korsinsky for Information Before October 13, 2026Aardvark Therapeutics, Inc. (AARD) - ACCESS Newswire
Aardvark Therapeutics, Inc. (AARD) Gets a Hold from RBC Capital - The Globe and Mail
AARD Investors Have Opportunity to Lead Aardvark Therapeutics, Inc. Securities Fraud Lawsuit ... - Black Hills Pioneer
AARD INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Aardvark Therapeutics, Inc. Stockholders with Losses Have Opportunity to Lead Class Action Lawsuit! - accessnewswire.com
Pomerantz Law Firm Announces the Filing of a Class Action Against Aardvark Therapeutics, Inc. and Certain Officers and DirectorsAARD - PR Newswire
AARD Lead Plaintiff Deadline is Quickly Approaching - GlobeNewswire
Aardvark Therapeutics, Inc. (AARD) Shareholders Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit - PR Newswire
Aardvark Therapeutics' ARD-101 Path Forward May Be Challenging, RBC Says - marketscreener.com
Class Action Alert: Levi & Korsinsky Reminds Aardvark Therapeutics, Inc. (AARD) Investors of October 13, 2026 Deadline - accessnewswire.com
SueWallSt Reminds Shareholders of a Lead Plaintiff Deadline of October 13, 2026 in Aardvark Therapeutics, Inc. LawsuitAARD - PR Newswire
SHAREHOLDER ALERT Bernstein Liebhard LLP Announces A - GlobeNewswire
AARD SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Aardvark Therapeutics, Inc. Stockholders with Losses Have Opportunity to Lead Class Action Lawsuit! - ACCESS Newswire
AARD LAWSUIT ALERT: Levi & Korsinsky Notifies Aardvark Therapeutics, Inc. InvestorsLead Plaintiff Deadline October 13, 2026 - ACCESS Newswire
Aardvark Therapeutics (AARD) Investors: Securities Fraud Class Action Filed, Contact Hagens Berman Before October 13, 2026 Lead Plaintiff Deadline - PR Newswire
Lawsuit alleges Aardvark Therapeutics misled in... - Pluang
Kuehn Law Encourages Investors of Aardvark Therapeutics, Inc. to Contact Law Firm - Morningstar
Did You Lose Money on Aardvark Therapeutics, Inc. (AARD)? Levi & Korsinsky Urges Investors to Act Before October 13, 2026 - ACCESS Newswire
Levi & Korsinsky Reminds Aardvark Therapeutics Investors of the Pending Class Action Lawsuit With a Lead Plaintiff Deadline of October 13, 2026AARD - PR Newswire
Layoff Tracker: Novo workforce down 13,000 - BioSpace
מועד אחרון לתביעה ייצוגית נגד AARDVARK: רוזן, יועץ למשקיעים מיומן, קורא למשקיעי Aardvark Therapeutics, Inc. לשכור ייצוג משפטי לקראת מועד חשוב בתביעה ייצוגית בניירות הערך – AARD - GlobeNewswire Inc.
Aardvark Therapeutics, Inc. (AARD) Investors with Substantial Losses Have Opportunity to Lead Aardvark Class Action Lawsuit Before October 13 Deadline - TMX Newsfile
AARD SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Aardvark Therapeutics, Inc. Shareholders with Losses Have Opportunity to Lead Class Action Lawsuit! - ACCESS Newswire
Bronstein, Gewirtz & Grossman LLC Urges Aardvark - globenewswire.com
AARDVARK THERAPEUTICS, INC. (AARD) SHAREHOLDER ALERT - GlobeNewswire
Important Notice to Long-Term Shareholders of Aardvark - GlobeNewswire
Aardvark Therapeutics Becomes Next Pharma Player To Quit Prader-Willi Syndrome Drug Development Efforts - Stocktwits
AARD Deadline: AARD Investors with Losses in Excess of $100K Have Opportunity to Lead Aardvark Therapeutics, Inc. Securities Fraud Lawsuit - AOL.ca
Deadline Alert: Aardvark Therapeutics, Inc. (AARD) - GlobeNewswire
AARD Investors Have Opportunity to Lead Aardvark Therapeutics, Inc. Securities Fraud Lawsuit with SBS Law - mykxlg.com
Lost Money on Aardvark Therapeutics, Inc. (AARD)? Urged to Join Class Action Before October 13, 2026Contact Levi & Korsinsky - ACCESS Newswire
AARD SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Aardvark Therapeutics, Inc. Stockholders with Substantial Losses Have Opportunity to Lead Class Action Lawsuit! - ACCESS Newswire
AARD IMPORTANT DEADLINE: ROSEN, TOP RANKED GLOBAL COUNSEL, - GlobeNewswire
AARD SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Aardvark Therapeutics, Inc. Shareholders Have Opportunity to Lead Class Action Lawsuit! - ACCESS Newswire
Lowey Dannenberg, P.C. is Investigating Aardvark - GlobeNewswire
AARD Investor Alert: Aardvark Therapeutics, Inc. Securities Class Action NoticeContact Levi & Korsinsky - The Chronicle-Journal
Aardvark Therapeutics Insider Sold Shares Worth $394,957, According to a Recent SEC Filing - Moomoo
AARD INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Aardvark Therapeutics, Inc. Stockholders Have Opportunity to Lead Class Action Lawsuit! - ACCESS Newswire
Robbins LLP is Investigating Allegations that Aardvark Therapeutics, Inc. Misled Investors Regarding the Viability and Efficacy of its Lead Drug Candidate ARD-101 - TMX Newsfile
Faruqi & Faruqi, LLP Urges Aardvark Therapeutics (AARD) Investors to Seek Counsel Before October 13, 2026 Lead Plaintiff Deadline in the Securities Class Action - TMX Newsfile
AARD Deadline Alert: SueWallSt Reminds Aardvark Therapeutics, Inc. (AARD) Investors of Securities Class Action Deadline on October 13, 2026 - PR Newswire
AARD Investors Have Opportunity to Lead Aardvark Therapeutics, Inc. Securities Fraud Lawsuit - The Conway Daily Sun
AARD INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Aardvark Therapeutics, Inc. Shareholders Have Opportunity to Lead Class Action Lawsuit! - ACCESS Newswire
AARD Investor Notice: Hagens Berman Alerts Investors in - GlobeNewswire
AARD UPCOMING DEADLINE: Levi & Korsinsky Alerts Aardvark Therapeutics, Inc. Stockholders of Securities Class ActionContact the Firm - PR Newswire
AARD SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Aardvark Therapeutics, Inc. Investors Have Opportunity to Lead Class Action Lawsuit! - accessnewswire.com
Bragar Eagel & Squire, P.C. Urges Aardvark Therapeutics, Inc. Investors to Contact the Firm Seeking Lead Plaintiff Role - GlobeNewswire
Pomerantz Law Firm Announces the Filing of a Class Action Against Aardvark Therapeutics, Inc. and Certain Officers and Directors – AARD - FinancialContent
AARD INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Aardvark Therapeutics, Inc. Investors Have Opportunity to Lead Class Action Lawsuit! - ACCESS Newswire
Aardvark Therapeutics Inc Stock (AARD) Financials Data
Revenue
Net Income
Cash Flow
EPS
3.06%
2.55%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):